Finasteride [For Androgenic Alopecia] interactions
Checked as Finasteride in this data source.
Full monograph for Finasteride [For Androgenic Alopecia]Check it against another medicine
Medicines
449 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Diltiazem Hydrochloride | Moderate | Metabolism | Coadministration with diltiazem may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased… | 11 sources — open the full entry |
| FluconazolebaseOphthalmic | Moderate | Metabolism | Coadministration with fluconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due… | 18 sources — open the full entry |
| Fluvoxamine Maleate | Moderate | Metabolism | Coadministration with fluvoxamine may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased… | 6 sources — open the full entry |
| Itraconazole | Moderate | Metabolism | Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism… | 19 sources — open the full entry |
| Larotrectinib | Moderate | Metabolism | Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. | 4 sources — open the full entry |
| Lefamulin Acetate | Moderate | Metabolism | When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Based on interaction with… | 6 sources — open the full entry |
| Nelfinavir | Moderate | Metabolism | Coadministration with nelfinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased… | 1 sources — open the full entry |
| Selpercatinib | Moderate | Metabolism | Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism… | 6 sources — open the full entry |
| Somatropin | Moderate | Metabolism | Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4. | 4 sources — open the full entry |
| Tacrolimus MonohydrateOralTopical | Moderate | Metabolism | Coadministration of sirolimus or tacrolimus with other drugs that are also metabolized by CYP450 3A4 may result in elevated plasma concentrations of the… | 7 sources — open the full entry |
| Voriconazole | Moderate | Metabolism | Coadministration with voriconazole may increase the plasma concentrations of drugs that are substrates of CYP450 2C19, 2C9, and/or 3A4. The mechanism is… | 9 sources — open the full entry |
| Terazosin Hydrochloride | Minor | Others | Study data (n=90) reported a statistically significant interaction between finasteride and terazosin affecting finasteride pharmacokinetics, but not those of… | 2 sources — open the full entry |
Conditions
Conditions in which Finasteride [For Androgenic Alopecia] needs care, as documented in this source.
Liver Diseases
ModerateFinasteride and dutasteride are extensively metabolized by the liver. Therapy with these drugs should be administered cautiously in patients with liver disease as exposure could be higher.
2 sources
- "Product Information. Proscar (finasteride)." Merck & Co., Inc (2002):
- "Product Information. Duagen (dutasteride)." GlaxoSmithKline Healthcare (2002):
Urethral Obstruction
ModeratePatients with large residual urinary volume and/or severely diminished urinary flow should be carefully monitored for obstructive uropathy. These patients may not be candidates for finasteride therapy.
1 source
- "Product Information. Proscar (finasteride)." Merck & Co., Inc (2002):